Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Arthritis, Rheumatoid 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 29avelumab 21Nivolumab 20Ipilimumab 10Radiotherapy 9Cyclophosphamide 9atezolizumab 8cemiplimab 7fludarabine 6Specimen Handling 6durvalumab 5aldesleukin 5Radiation 5Magnetic Resonance Spectroscopy 5Interleukin-2 5Biopsy 5talimogene laherparepvec 4ALT-803 4poly ICLC 3Radiosurgery 3Etoposide 3Cisplatin 3Carboplatin 3CTLA-4 Antigen 3Bevacizumab 3prednylidene 2lutetium Lu 177 dotatate 2fludarabine phosphate 2domatinostat 2deltacortene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × tocilizumab × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡